PAM50, Subtype May Identify Node-Positive Breast Cancer

Share this content:
PAM50 risk of recurrence score and intrinsic subtype may be able to identify node-positive breast cancer with limited risk of metastasis.
PAM50 risk of recurrence score and intrinsic subtype may be able to identify node-positive breast cancer with limited risk of metastasis.

After endocrine therapy in women with hormone receptor positive (HR+) breast cancer, PAM50 risk of recurrence (ROR) score and intrinsic subtype may be able to identify node-positive patients with limited risk of metastasis, according to a recent study published in Annals of Oncology.

Michael Gnant, MD, of the Medical University of Vienna and fellow researchers looked at tissue specimens of 543 node positive patients who received adjuvant tamoxifen and/or anastrozole.

“As most node-positive patients with HR+ breast cancer currently receive adjuvant chemotherapy improved methods for characterization of individuals' metastasis risk are needed to reduce overtreatment,” they noted.

Primary objective was to evaluate prognostic information of ROR score with combined clinical standard variables in patients with one positive node (1N+) or two/three positive nodes (2-3N+).

The authors found that, upon multivariate analysis, PAM50-derived ROR score provided reliable prognostic information beyond established clinical factors for patients with both 1N+ and 2-3N+.

The 10-year distant recurrence risk was significantly increased in the high-risk group based on ROR score for 1N+, compared to the low-risk group, as well as the combined low/intermediate risk group for patients with 2-3N+.

RELATED: In Breast Cancer, Self-Reported Health Predicts Survival

In addition, luminal A intrinsic subtype demonstrated a significantly lower risk of distant recurrence in patients with 1N+ and 2-3N+ compared to luminal B subtype.

“The PAM50 test is a valuable tool in determining treatment for node-positive early breast cancer patients,” the authors concluded.

Reference

  1. Gnant, M., et al. "Identifying Clinically Relevant Prognostic Subgroups of Postmenopausal Women with Node-positive Hormone Receptor Positive Early Stage Breast Cancer Treated with Endocrine Therapy: A combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype." Annals of Oncology. doi: 10.1093/annonc/mdv215. [epub ahead of print]. May 1, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs